跳至主要内容
临床试验/NCT00003261
NCT00003261Unknown2 期

Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy

Centro di Riferimento Oncologico - Aviano1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 1997年5月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
14
试验地点
1
主要终点
Efficacy

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving methotrexate and zidovudine together with radiation therapy works in treating patients with HIV-related primary central nervous system lymphoma.

详细描述

OBJECTIVES:

  • Determine the efficacy of neoadjuvant chemotherapy and radiation therapy in the treatment of HIV-related primary CNS lymphoma patients.
  • Evaluate the toxicity and overall survival of these patients.

OUTLINE: Patients receive chemotherapy consisting of high-dose methotrexate IV administered on day 1 and high-dose zidovudine IV administered on days 1-3 every 2 weeks. Patients receive 3 courses of therapy. Following chemotherapy, patients receive radiation therapy to the lesion site daily.

Patients are followed every 3 months for 1 year and then every 6 months thereafter.

PROJECTED ACCRUAL: This study will accrue 14 patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Histologically proven HIV-related non-Hodgkin's lymphoma of the CNS
  • •No systemic lymphoma
  • •PATIENT CHARACTERISTICS:
  • •18 and over
  • •Performance status:
  • •Life expectancy:
  • •Not specified
  • •Hematopoietic:
  • •WBC at least 3000/mm^3
  • •Platelet count at least 80,000/mm^3
  • •No serious impairment of liver function
  • •No serious impairment of renal function
  • •Creatinine clearance at least 40 mL/min
  • •Cardiovascular:
  • •No serious impairment of cardiac function
  • •Neurologic:
  • •Neurological functional status 0-3
  • •No prior or active CNS-opportunistic infections
  • •No AIDS dementia complex
  • •No active systemic infections
  • •PRIOR CONCURRENT THERAPY:
  • •No prior chemotherapy or radiotherapy

排除标准

  • 未提供

结局指标

主要结局

Efficacy

Toxicity

Overall survival

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验